FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3112379566> ?p ?o ?g. }

• W3112379566 endingPage "S244" @default.
• W3112379566 startingPage "S244" @default.
• W3112379566 abstract "Context Long-term TKI treatment is related to notable adverse events, quality-of-life impact, and significant costs to health systems. TFR has been shown to be safe in multiple clinical trials, so it has become a new goal for CML management, although information about TFR in Colombia is scarce. Objective Our aim is to show the outcomes of TFR in Colombia. Design The Colombian Association of Hematology and Oncology (ACHO)'s hematological disease registry (RENEHOC) is a multicenter study that has collected information in 14 centers with Institutional Ethics Committee approval. This report represents a sub-analysis of the patients in the registry in whom discontinuation was performed. Setting RENEHOC is a nationwide, multicenter registry on hematologic malignancies that captures information from academic and general community centers. Since 2019, it has been collecting information on CML. Patients or other participants A total of 357 CML adult patients treated in the last 20 years have been registered until now on RENEHOC. Twenty patients were considered candidates for TFR; in 14 of them, TKI have been discontinued. Interventions Treatment was according to investigator preferences. Ten patients received Imatinib as first-line and ten received second-generation TKI. Four required a second line (Nilotinib); three due to intolerance. Nine patients discontinued in a standardized TFR program, three with the intention to seek a pregnancy, one for toxicity (pleural effusion), and one for personal reasons. Main outcome measures The main outcome measured is survival without TKI re-initiation. Results The mean age was 56 yrs. (25–92), 11 were women, and 19 were in the chronic phase. On average, they received 9.3 years of TKI (3.2–14) and were in RMM for 6.9 years before TFR. At a median follow-up of 15.2 months (range 1–44.5), 12 patients remain TKI-free; the patients that re-initiated TKI regained 4.5 MMR. Five patients developed withdrawal syndrome. Conclusions The TFR is a real goal for a selected group of patients with CML. This report represents real-world data in Colombia, showing its feasibility and safety under well-controlled settings. Funding ACHO has received grants for RENEHOC project from Takeda, Abbvie, Amgen, Dr. Reddy's. Long-term TKI treatment is related to notable adverse events, quality-of-life impact, and significant costs to health systems. TFR has been shown to be safe in multiple clinical trials, so it has become a new goal for CML management, although information about TFR in Colombia is scarce. Our aim is to show the outcomes of TFR in Colombia. The Colombian Association of Hematology and Oncology (ACHO)'s hematological disease registry (RENEHOC) is a multicenter study that has collected information in 14 centers with Institutional Ethics Committee approval. This report represents a sub-analysis of the patients in the registry in whom discontinuation was performed. RENEHOC is a nationwide, multicenter registry on hematologic malignancies that captures information from academic and general community centers. Since 2019, it has been collecting information on CML. A total of 357 CML adult patients treated in the last 20 years have been registered until now on RENEHOC. Twenty patients were considered candidates for TFR; in 14 of them, TKI have been discontinued. Treatment was according to investigator preferences. Ten patients received Imatinib as first-line and ten received second-generation TKI. Four required a second line (Nilotinib); three due to intolerance. Nine patients discontinued in a standardized TFR program, three with the intention to seek a pregnancy, one for toxicity (pleural effusion), and one for personal reasons. The main outcome measured is survival without TKI re-initiation. The mean age was 56 yrs. (25–92), 11 were women, and 19 were in the chronic phase. On average, they received 9.3 years of TKI (3.2–14) and were in RMM for 6.9 years before TFR. At a median follow-up of 15.2 months (range 1–44.5), 12 patients remain TKI-free; the patients that re-initiated TKI regained 4.5 MMR. Five patients developed withdrawal syndrome. The TFR is a real goal for a selected group of patients with CML. This report represents real-world data in Colombia, showing its feasibility and safety under well-controlled settings." @default.
• W3112379566 created "2020-12-21" @default.
• W3112379566 creator A5016923150 @default.
• W3112379566 creator A5031783317 @default.
• W3112379566 creator A5032449450 @default.
• W3112379566 creator A5047320398 @default.
• W3112379566 creator A5051345251 @default.
• W3112379566 creator A5078192711 @default.
• W3112379566 date "2020-09-01" @default.
• W3112379566 modified "2023-09-27" @default.
• W3112379566 title "CML-411: Treatment-Free Remission in Patients with Chronic Myeloid Leukemia (CML): A Real-World Cohort of Patients in Colombia" @default.
• W3112379566 doi "https://doi.org/10.1016/s2152-2650(20)30834-x" @default.
• W3112379566 hasPublicationYear "2020" @default.
• W3112379566 type Work @default.
• W3112379566 sameAs 3112379566 @default.
• W3112379566 citedByCount "1" @default.
• W3112379566 countsByYear W31123795662021 @default.
• W3112379566 crossrefType "journal-article" @default.
• W3112379566 hasAuthorship W3112379566A5016923150 @default.
• W3112379566 hasAuthorship W3112379566A5031783317 @default.
• W3112379566 hasAuthorship W3112379566A5032449450 @default.
• W3112379566 hasAuthorship W3112379566A5047320398 @default.
• W3112379566 hasAuthorship W3112379566A5051345251 @default.
• W3112379566 hasAuthorship W3112379566A5078192711 @default.
• W3112379566 hasConcept C118552586 @default.
• W3112379566 hasConcept C126322002 @default.
• W3112379566 hasConcept C142724271 @default.
• W3112379566 hasConcept C151730666 @default.
• W3112379566 hasConcept C204787440 @default.
• W3112379566 hasConcept C27415008 @default.
• W3112379566 hasConcept C2777413986 @default.
• W3112379566 hasConcept C2777583451 @default.
• W3112379566 hasConcept C2778715236 @default.
• W3112379566 hasConcept C2778729363 @default.
• W3112379566 hasConcept C2779343474 @default.
• W3112379566 hasConcept C512399662 @default.
• W3112379566 hasConcept C535046627 @default.
• W3112379566 hasConcept C68122502 @default.
• W3112379566 hasConcept C71924100 @default.
• W3112379566 hasConcept C72563966 @default.
• W3112379566 hasConcept C86803240 @default.
• W3112379566 hasConceptScore W3112379566C118552586 @default.
• W3112379566 hasConceptScore W3112379566C126322002 @default.
• W3112379566 hasConceptScore W3112379566C142724271 @default.
• W3112379566 hasConceptScore W3112379566C151730666 @default.
• W3112379566 hasConceptScore W3112379566C204787440 @default.
• W3112379566 hasConceptScore W3112379566C27415008 @default.
• W3112379566 hasConceptScore W3112379566C2777413986 @default.
• W3112379566 hasConceptScore W3112379566C2777583451 @default.
• W3112379566 hasConceptScore W3112379566C2778715236 @default.
• W3112379566 hasConceptScore W3112379566C2778729363 @default.
• W3112379566 hasConceptScore W3112379566C2779343474 @default.
• W3112379566 hasConceptScore W3112379566C512399662 @default.
• W3112379566 hasConceptScore W3112379566C535046627 @default.
• W3112379566 hasConceptScore W3112379566C68122502 @default.
• W3112379566 hasConceptScore W3112379566C71924100 @default.
• W3112379566 hasConceptScore W3112379566C72563966 @default.
• W3112379566 hasConceptScore W3112379566C86803240 @default.
• W3112379566 hasLocation W31123795661 @default.
• W3112379566 hasOpenAccess W3112379566 @default.
• W3112379566 hasPrimaryLocation W31123795661 @default.
• W3112379566 hasRelatedWork W1915791887 @default.
• W3112379566 hasRelatedWork W2011020866 @default.
• W3112379566 hasRelatedWork W2133399638 @default.
• W3112379566 hasRelatedWork W2276860160 @default.
• W3112379566 hasRelatedWork W2462710785 @default.
• W3112379566 hasRelatedWork W2484136943 @default.
• W3112379566 hasRelatedWork W2900357627 @default.
• W3112379566 hasRelatedWork W3173034120 @default.
• W3112379566 hasRelatedWork W3181348305 @default.
• W3112379566 hasRelatedWork W635066634 @default.
• W3112379566 hasVolume "20" @default.
• W3112379566 isParatext "false" @default.
• W3112379566 isRetracted "false" @default.
• W3112379566 magId "3112379566" @default.
• W3112379566 workType "article" @default.